{
  "docId": "019de070-c58c-706c-98f1-9eec26811648",
  "docSlug": "2a1e5b2d3a1cb25fe50abb3e75ae9bdf",
  "documentTitle": "Alkermes | Investor Day Presentation Deck | 144 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 103,
  "pageCount": 132,
  "prevPage": 102,
  "nextPage": 104,
  "slideType": "problem_statement",
  "function": "frame_problem",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-c58c-706c-98f1-9eec26811648/103",
  "deckHref": "/decks/019de070-c58c-706c-98f1-9eec26811648",
  "deckJsonHref": "/decks/019de070-c58c-706c-98f1-9eec26811648.json",
  "deckAnchorHref": "/decks/019de070-c58c-706c-98f1-9eec26811648#slide-103",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.35,
        "x": 0.58,
        "y": 0.25
      },
      "kind": "callout",
      "text": "Alkermes design intentions for engineered IL-12:\nHarness the therapeutic potential of IL-12\nAddress delivery challenges associated with IT approaches\nAvoid toxicity associated with systemic exposure to IL-12",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6f3210ec-6ac6-4af4-90a7-9c51616aaae3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.45,
        "x": 0.05,
        "y": 0.62
      },
      "kind": "list",
      "text": "Gene therapy, viral delivery, electroporation, nanoparticles\nPrimarily based on intratumoral (IT) administration",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "27096d4e-6e2c-4a18-93d3-0c6ab6f8030f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.45,
        "x": 0.05,
        "y": 0.38
      },
      "kind": "list",
      "text": "Systemic administration associated with the potential for rapid development of lethal inflammatory syndrome",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3d5a41b2-fedc-4cd7-81d5-b2f8c5648c55",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.45,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "paragraph",
      "text": "Clinical evaluation limited due to severe toxicities associated with systemic exposure to IL-12 and its narrow therapeutic index1,2, 3",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "012783c0-33ba-406e-aec4-ba131b358f30",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.45,
        "x": 0.05,
        "y": 0.52
      },
      "kind": "paragraph",
      "text": "Ongoing efforts in biopharma seeking to develop strategies for tumor-localized IL-12 delivery1,2",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "882fe65e-a60f-470c-ba35-4d80a478554b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.4,
        "x": 0.05,
        "y": 0.85
      },
      "kind": "source-note",
      "text": "1. Nguyen KG et. al. Cancer Immunotherapy. Front. Immunol. October 15 2020 11:575597\n2. Vecchio MD et. al. Clin Cancer Res August 15 2007 (13) (16) 4677-4685\n3. Strauss J et. al. Clin Cancer Res January 1 2019 (25) (1) 99-109",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7934f5fe-1e77-41c0-a7c9-beb12ac563a5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.85,
        "x": 0.05,
        "y": 0.12
      },
      "kind": "title",
      "text": "IL-12 Potential Clinical Utility Limited by Severe Toxicities",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5ba7c8ef-e28e-4d1b-be34-823ddf5a9b7e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Problem Statement Canvas",
      "slug": "problem-statement-canvas",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "430718b4-c012-4b16-9467-16900c751c96",
      "evidence": "Clinical evaluation limited due to severe toxicities associated with systemic exposure to IL-12 and its narrow therapeutic index",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}